Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB
Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1583-1589
DOI: 10.1111/jgh.70326 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 08.03.2026. Verfasst von Seong Hee Kang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Tenofovir, Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Korea University Ansan Hospital Grant, National Research Foundation of Korea (NRF) grant funded by the Korean government, Korea University Research Grant.
Abstract (Originalsprache)
Background
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are guideline‐endorsed first‐line options for antiviral‐naive chronic hepatitis B (CHB). We compared their associations with hepatocellular carcinoma (HCC) occurrence.
Methods
We assembled a multicenter cohort of 1364 treatment‐naive CHB patients initiating either TAF ( n = 322) or TDF ( n = 1042) between 2012 and 2019. Confounding was addressed using 1:2 propensity score (PS) matching and inverse probability of treatment weighting (IPTW).
Results
The PS‐matched analytic set comprised 966 patients (TAF 322; TDF 644). Over 60 months, nine HCC events occurred (two TAF and seven TDF events). Crude incidence rates were 0.17 and 0.27 per 100 person‐years for TAF and TDF, respectively. Five‐year cumulative risks were 0.6% (TAF) versus 1.0% (TDF). In multivariable models, TAF remained protective (adjusted hazard ratio [aHR]: 0.29, 95% confidence interval [CI]: 0.13–0.66; p < 0.01). Findings were directionally consistent across subgroups, with the strongest associations observed among patients without diabetes, those who were hepatitis B e antigen–positive, and those with baseline HBV DNA in the 5–8 log10 IU/mL range. In IPTW analyses, TAF was likewise associated with lower HCC risk (aHR: 0.31, 95% CI: 0.14–0.68; p < 0.01).
Conclusions
Compared with TDF, TAF use was associated with an approximately 71% reduction in HCC hazard. Larger cohorts with longer follow‐up are warranted to corroborate these observations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
- Department of Internal Medicine, Gachon University College of Medicine, Incheon, Republic of Korea.
ORCID-Profile: Hyung Joon Yim, Young-Sun Lee, Seung Kak Shin, Moon Young Kim, Yeon Seok Seo
Förderung
- Korea University Ansan Hospital Grant
- National Research Foundation of Korea (NRF) grant funded by the Korean government
- Korea University Research Grant
- Basic Science Research Program through the National Research Foundation of Korea
- Medical Research Center Program
- Ministry of Science, ICT, and Future Planning
- The Korean Association for the Study of the Liver
- The Korean Liver Foundation
Zitieren
APA
Kang, S. H., Yim, H. J., Han, S. K., Yim, S. Y., Kim, T. H., Lee, Y. S., Shin, S. K., Jung, Y. K., Kim, M. Y., Kim, J. H., Seo, Y. S., Kwon, O. S., Yeon, J. E., & Baik, S. K. (2026). Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. Journal of Gastroenterology and Hepatology, 41(5), 1583-1589. https://doi.org/10.1111/jgh.70326
Vancouver
Kang SH, Yim HJ, Han SK, Yim SY, Kim TH, Lee YS, et al. Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. Journal of Gastroenterology and Hepatology. 2026;41(5):1583-1589. doi:10.1111/jgh.70326
BibTeX
@article{Kang2026,
author = {Kang, Seong Hee and Yim, Hyung Joon and Han, Seul Ki and Yim, Sun Young and Kim, Tae Hyung and Lee, Young-Sun and Shin, Seung Kak and Jung, Young Kul and Kim, Moon Young and Kim, Ji Hoon and Seo, Yeon Seok and Kwon, Oh Sang and Yeon, Jong Eun and Baik, Soon Koo},
title = {Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {5},
pages = {1583--1589},
doi = {10.1111/jgh.70326}
}
EUVIMED